Cahill Financial Advisors Inc. grew its position in Novo Nordisk A/S (NYSE:NVO – Free Report) by 14.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,859 shares of the company’s stock after purchasing an additional 500 shares during the period. Cahill Financial Advisors Inc.’s holdings in Novo Nordisk A/S were worth $551,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. GQG Partners LLC increased its position in shares of Novo Nordisk A/S by 654.6% during the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after acquiring an additional 3,151,584 shares in the last quarter. Capital International Investors grew its position in Novo Nordisk A/S by 22.3% in the fourth quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock valued at $736,121,000 after purchasing an additional 1,297,536 shares in the last quarter. Acadian Asset Management LLC grew its position in Novo Nordisk A/S by 1,300.8% in the first quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock valued at $159,703,000 after purchasing an additional 1,155,313 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Novo Nordisk A/S by 10.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock valued at $1,102,857,000 after purchasing an additional 823,036 shares in the last quarter. Finally, Norden Group LLC grew its position in Novo Nordisk A/S by 2,456.0% in the first quarter. Norden Group LLC now owns 658,856 shares of the company’s stock valued at $84,597,000 after purchasing an additional 633,079 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Stock Performance
Shares of NVO opened at $131.93 on Tuesday. The firm has a 50-day moving average of $134.52 and a 200-day moving average of $132.68. Novo Nordisk A/S has a one year low of $86.96 and a one year high of $148.15. The company has a market cap of $592.04 billion, a PE ratio of 45.49, a price-to-earnings-growth ratio of 1.43 and a beta of 0.42. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75.
Novo Nordisk A/S Cuts Dividend
The business also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is presently 24.83%.
Wall Street Analyst Weigh In
NVO has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price for the company. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday. Argus raised their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. Finally, BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $145.17.
Get Our Latest Research Report on NVO
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
- Five stocks we like better than Novo Nordisk A/S
- What Are Some of the Best Large-Cap Stocks to Buy?
- Why Block’s Key Components Make It a Solid Investment Choice
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- Want to Profit on the Downtrend? Downtrends, Explained.
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.